Clinical trials
Phase 1/2 Polycythemia Vera trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Recruiting | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 3 |
| Ronald Hoffman | 2 |
| Ascentage Pharma Group Inc. | 1 |
| Cancer Treatment Centers of America | 1 |
| Drexel University College of Medicine | 1 |
| Incyte Corporation | 1 |
| M.D. Anderson Cancer Center | 1 |
| Mayo Clinic | 1 |
| NS Pharma, Inc. | 1 |
| OHSU Knight Cancer Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Polycythemia Vera | 19 |
| Primary Myelofibrosis | 16 |
| Thrombocythemia, Essential | 14 |
| Myeloproliferative Disorders | 13 |
| Leukemia, Myeloid, Acute | 8 |
| Myelodysplastic Syndromes | 7 |
| Leukemia | 6 |
| Leukemia, Myelomonocytic, Chronic | 6 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
| Leukemia, Neutrophilic, Chronic | 5 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.